Smart contract address: 0x3A1e35AFB24ECBAe7964E7559f1f99cBF39F0466
Token ID: 0
Wallet address: 0x8b88cfaf997dc2510435b2d523728741cb703bb0
Network: Ethereum
This work is unique.
Minted on 18 June 2022
Special notice
Please note for tax purposes, including potential sales tax, NFTs may be considered a digital service or digital product and thus Christie’s may be required to collect relevant taxes dependent on local laws. For tax rate information, you may wish to consult an independent tax advisor. Please note, except in the event you are a resident of Mainland China, you may elect to make payment of the purchase price for this lot in the cryptocurrency Ether or in the cryptocurrency Bitcoin. Payment in Ether or Bitcoin must be made via a digital wallet transfer of Ether or Bitcoin to Christie’s. If you do not already have one, please obtain a hosted digital wallet at Coinbase Custody Trust; Coinbase, Inc.; Fidelity Digital Assets Services, LLC; Gemini Trust Company, LLC; or Paxos Trust Company, LLC. The digital wallet must be registered to you, or, if you registered to bid as a company, then in the name of the company. Please note that setting up a digital wallet can take a week or more, depending on the service provider’s account opening requirements. Only payments sent from digital wallets maintained at the above listed platforms will be accepted. We will not recognize payments from digital wallets hosted at other exchanges or self-hosted wallets. Partial payments of a lot from multiple digital wallets are not allowed. You agree, upon our request, to provide documentation confirming that the Ether or Bitcoin payment was made from a digital wallet registered in your name and maintained at one of the platforms listed above. You must notify us within 24 hours of sale closing should you wish to pay by cryptocurrency. The cryptocurrency amount will be calculated by us based on the most recent published CoinDesk Ether Price Index (ETX) or CoinDesk Bitcoin Price Index (XBX) as determined by us at the time the sale closes and will be disclosed in the invoice. For further information and to view our Buyers Premium rates, please view the Conditions of Sale via the link below.
Sale Room Notice
This NFT includes only a modified digital image of US Patent Nos. 8,278,036 and 8,691,966. THIS NFT DOES NOT INCLUDE OR TRANSFER ANY RIGHT, TITLE, INTEREST OR LICENSE IN, TO, OR UNDER US PATENT NOS. 8,278,036 OR 8,691,966 OR ANY OTHER PATENT OR TECHNOLOGY.
Brought to you by

Lot Essay

THE UNIVERSITY OF PENNSYLVANIA MRNA NFT - VACCINES FOR A NEW ERA. An NFT, issued in a single edition only, memorializing the pioneering work of Drs. Drew Weissman and Katalin Karikó and its impact on mRNA vaccines against the COVID-19 virus. The NFT includes a three-dimensional video illustrating the mechanics of this mRNA vaccine technology at the microscopic level which is complemented with a copy of original patent documents, and a letter from Dr. Drew Weissman. The NFT also includes an additional version of the video bearing captions describing the action on-screen as well as a storyboard “explainer” allowing the viewer to better understand the mechanics of how mRNA works to stimulate the immune system to defend against COVID-19.

The story begins beside a simple photocopier in 1998 at the University of Pennsylvania. Drs. Weissman and Karikó were both attempting to copy lengthy research papers and in the course of negotiating who could use the machine first, they began discussing their own research. Dr. Weissman had been investigating the use of DNA to produce an HIV vaccine. Dr. Karikó argued for RNA as an alternative. Intrigued, Dr. Weissman asked her to collaborate with his team. The partnership proved to be an excellent fit: Dr. Weissman was an experienced immunologist while Dr. Karikó had worked extensively with RNA.

The collaboration proved extremely fruitful. Dr. Weissman recalled, “We shared knowledge. We shared papers. We taught each other everything. But by doing that, it allowed us to figure out how to make modified mRNA and how it could help make a vaccine. But for my chance meeting and subsequent collaboration with Dr. Karikó, we would not have made this discovery of modified mRNA because we needed both elements, both types of science involved.” A longstanding hurdle to introducing unmodified mRNA into a living organism was inflammation, which could prove deadly—a hurdle largely overcome by mRNA modifications discovered by Drs. Weissman and Karikó. They also found that encasing the modified mRNA in lipid (fat) droplets prevented the immune system from immediately attacking it as a foreign invader, allowing the modified mRNA to work in concert with the immune system to fight disease.

Although they published their landmark research paper on their discoveries in 2005, the medical research community initially paid little attention to this important breakthrough. It was not until more than a decade later that mRNA technology was found to be one of the most effective means of developing vaccines quickly and effectively. As soon as the genome for COVID-19 had been sequenced and released, vaccine developers around the world, including Dr. Weissman and his team and collaborators, were able to begin researching a potential mRNA vaccine and within weeks, they were conducting their first mRNA vaccine tests in animals. Today, over a billion mRNA-based vaccine doses have been administered worldwide.

The foundational modified mRNA technology developed by Drs. Weissman and Karikó is not limited to vaccines protecting against COVID-19. As Dr. Weissman notes in his letter attached to the NFT: “I think mRNA has huge potential opportunities for treating and preventing many different diseases. My team and I are currently at work on a pan-coronavirus vaccine to stop the next coronavirus epidemic, a universal flu vaccine, and vaccines to prevent herpes and malaria. We are also working with colleagues to develop cancer therapeutics with mRNA technology. My laboratory also supports the development of mRNA vaccines and production facilities with other countries to help nations with fewer financial resources than the United States gain improved access to this lifesaving technology. We are also using mRNA technology as a new potential treatment for certain genetic disorders, including sickle cell anemia, with a single injection of mRNA- LNPs targeted to bone marrow stem cells to allow the mRNA to express gene editing enzymes that can correct this genetic disorder. I believe mRNA technology can be further developed for much broader use in the future to treat numerous other genetic diseases as well as many acute and chronic diseases.”

Funds raised by the sale of the NFT will be used to advance important research across the university.

“The stunning speed with which the mRNA COVID-19 vaccines were developed and their global success in fighting the pandemic has led to an explosion of interest in how modified mRNA technology can be applied across many fields of medicine,” said J. Larry Jameson, MD, PhD, Executive Vice President of the University of Pennsylvania for the Health System and Dean of the Perelman School of Medicine. “Dr. Weissman and his colleagues across Penn are continuing to chart new paths of discovery with the potential for global impact. This digital asset celebrates their historic scientific achievements and points to a bright future in vaccine research and development.” The development of the NFT celebrating mRNA discoveries was led by the Wharton School’s Stevens Center for Innovation in Finance, which includes a Blockchain Laboratory, in collaboration with Penn Medicine and the Penn Center for Innovation, the university’s hub for technology commercialization and entrepreneurship.

Related Articles

Sorry, we are unable to display this content. Please check your connection.

More from
The University of Pennsylvania mRNA NFT - Vaccines for a New Era
Place your bid Condition report

A Christie's specialist may contact you to discuss this lot or to notify you if the condition changes prior to the sale.

I confirm that I have read this Important Notice regarding Condition Reports and agree to its terms. View Condition Report